Archives

by in
Entry Author Date Location
Trubion Wins Genentech, Biogen Patent Case 06/03/10 Seattle
Seattle Genetics, Growing Up in a Hurry With Millennium, Aims to Make Most of Cancer Drug 05/26/10 Seattle
Dendreon Makes History: FDA Approves First Active Immune-Booster to Fight Cancer 04/29/10 Seattle
Dendreon Hires Roche Sales Boss 04/08/10 Seattle
FDA Cancer Drug Boss Slams Cell Therapeutics Application For Lymphoma Drug 03/22/10 Seattle
Roche, Biogen Halt Arthritis Study 03/08/10 Boston
Lycera, a Midwestern Biotech Star, Moves Head Office to Boston, Hires Biogen Vet as CEO 01/07/10 Boston
Adimab Proves Fast Antibody Discovery Tool to Merck, Roche; Snags New Deal With Pfizer 12/17/09 Boston
Roche Scraps Partnership With Seattle Genetics on Lymphoma Drug 12/11/09 Seattle
Dendreon Grasps for $400M, ZymoGenetics Cuts 52 Jobs, Calistoga Advances at ASH, & More Seattle-Area Life Sciences News 12/10/09 Seattle
Biogen Idec’s Dream: Antibodies That Kill Two Birds With One Stone 12/09/09 Boston
Seattle Genetics, Genentech Lymphoma Drug Passes Early Test with “Naked” Antibody 12/07/09 Seattle
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore 11/19/09 Boston
Calistoga Cancer Drug Shows “Encouraging” Preliminary Results in Small Study 10/19/09 Seattle
Seattle Genetics Shares Drop on Halted Lymphoma Trial 10/05/09 Seattle
Seattle Genetics, Bucking the Trend, Recruits Hodgkin’s Patients at Warp Speed 08/12/09 Seattle
Biogen Idec, Trying to Go Beyond Rituxan, Assembles Cancer Drug Pipeline 07/16/09 Boston
Agios Lands Genentech Cancer Drug Leader as New CEO 05/27/09 Boston
How to Raise $50M in a Recession: Highlights from the Xconomy Life Sciences Forum 05/01/09 Boston
Biogen Idec, Extending Life of its Top-Selling Drug, Eyes Longer-Lasting Shot for MS 03/27/09 Boston
Trubion Starts Lupus Trial 03/25/09 Seattle
Biogen Idec, Genentech’s Rituxan Fails in Pivotal Study of Lupus of Kidneys 03/11/09 Boston
Trubion Cuts One-Fourth of Workforce 02/25/09 Seattle
Pfizer’s Bid For Wyeth Sends Ripples Through Trubion Pharmaceuticals, Seattle Biotechs 01/27/09 Seattle
Biogen Idec VC Group Sees Opportunity in Tough Market, Has $100M New Allocation to Invest in Biotech Firms 12/12/08 San Diego
Blood News: A Quick Rundown of Headlines From the American Society of Hematology 12/09/08 National
Seattle Genetics “Empowered Antibody” Shines at Blood Disease Meeting 12/06/08 Seattle
Biogen Pays $31.5M to Genentech to Co-Develop Anti-CD20 Drug 11/03/08 Boston
Trubion Shares Leap, Drop, Leap Again After Encouraging Clinical Trial News 10/27/08 Seattle
Calistoga Builds Cancer Drug Strategy, Hires First CEO, Carol Gallagher 10/08/08 Seattle
Page 2 of 3 « previous page · next page »